David Bredt, Chief Scientific Officer at Rapport Therapeutics, Inc. (RAPP), sold 17,000 shares at $25.39 ($428K) on 2025-11-17, disclosed to the SEC on 2025-11-18.
Scheduled sale ($428k) by Chief Scientific Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $24.84 | 3,156 | $78K | 18.3% |
| 2 | $24.84 | 3,156 | $78K | 18.3% |
| 3 | $25.39 | 5,344 | $136K | 31.7% |
| 4 | $25.39 | 5,344 | $136K | 31.7% |
| Total | $25.19 avg | 17,000 | $428K | 100% |
| Filing → |
| RAPP | SELL | 2026-01-05 | $395K | — | Filing → |
| RAPP | SELL | 2025-12-16 | $486K | — | Filing → |
| RAPP | SELL | 2025-10-16 | $410K | — | Filing → |